Stockreport

Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves [Yahoo! Finance]

Viatris Inc.  (VTRS) 
PDF On December 9, Barclays analyst Glen Santangelo initiated coverage of Viatris Inc. (NASDAQ:VTRS) with an Overweight rating and a $15 price target. The firm launched cov [Read more]